September 18, 2008
Dermatologists Continue to Use Enbrel Over Humira As First-Line Biologic Therapy for the Treatment of Psoriasis
WALTHAM, Mass., Sept. 18 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that 77 percent of surveyed dermatologists name Amgen/Wyeth/Takeda's Enbrel as their preferred first-line biologic therapy. The critical factors driving surveyed dermatologists' use of Enbrel ahead of Abbott/Eisai's Humira are its perceived better side-effect/safety profile and wealth of long-term safety data, as well as their own familiarity with the drug.
The new report entitled Treatment Algorithms in Psoriasis finds that 60 percent of surveyed dermatologists choose Enbrel as a first-line biologic therapy because of their familiarity and experience with the drug; 59 percent choose Enbrel because of their perception that its side-effect/safety profile is superior to that of Humira. On the other hand, surveyed dermatologists who choose to prescribe Humira over Enbrel do so for very different reasons. Fifty-one percent of surveyed dermatologists state that Humira's less frequent dosing (once every two weeks versus once or twice weekly) influences their choice of this agent over Enbrel as a first-line biologic therapy and 45 percent prescribe Humira as a first-line biologic drug because of its better efficacy in clearing psoriatic plaques."Enbrel and Humira each garner more second- and third-line patient share in our current analysis compared with our 2007 report," said Madhuri Borde, Ph.D., analyst at Decision Resources. "While Enbrel leads Humira in each line of therapy, our physician survey data suggests that Humira's growing penetration of early-line treatment in psoriasis will continue through 2010, in part at the expense of declining use of Genentech/Merck Serono's T-cell modulator Raptiva."
The report also finds that 66 percent of surveyed dermatologists who are familiar with Centocor/ Medarex/Janssen-Cilag's interleukin-12/23 inhibitor Stelara (ustekinumab) plan to prescribe the drug when it becomes available. Stelara is generating excitement among interviewed experts because of its high response rates and the potential for long-term remissions. Surveyed dermatologists who expect to incorporate Stelara into their therapeutic arsenal say that the greatest percentage of its total use will stem from second-line therapy. This physician group estimates that 20 percent of their use of Stelara will be in first-line therapy, whereas 40 percent of their prescriptions for the drug will be as a second-line treatment.
About Treatment Algorithm Insight Series
Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from PharMetrics(R) to provide exceptional insight into physicians' prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.
About Decision Resources
Decision Resources ( http://www.decisionresources.com/ ) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.decisionresourcesinc.com/ .
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Natalia Morales Elizabeth Marshall Decision Resources Decision Resources, Inc. 781-296-2691 781-296-2563 [email protected] [email protected]
Web site: http://www.decisionresources.com/http://www.decisionresourcesinc.com/